Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

115.96 +0.05 (+0.04%)

Streaming Delayed Price Updated: 3:40 PM EDT, Mar 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	4,250,661
Open	116.92
Bid (Size)	115.96 (300)
Ask (Size)	115.99 (100)
Prev. Close	115.91
Today's Range	115.82 - 117.89
52wk Range	73.31 - 125.14
Shares Outstanding	2,531,374,696
Dividend Yield	2.93%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm

Today 14:12 EDT

In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in...

Via MarketMinute

The Dividend Shield: How Meta, Microsoft, Merck, and Target are Signal-Boosting Balance Sheet Strength in a Cooling 2026 Economy

Today 12:01 EDT

As of March 13, 2026, the global financial landscape is navigating a delicate transition. Following the aggressive rate hikes of previous years and a subsequent "soft landing" throughout 2025, the U.S....

Via MarketMinute

Performance

YTD	+8.9%	+8.9%
1 Month	-1.0%	-1.0%
3 Month	+17.1%	+17.1%
6 Month	+36.2%	+36.2%
1 Year	+24.2%	+24.2%

More News

Today 0:39 EDT

Via StockStory

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

Via MarketMinute

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

Via Finterra

2 Dow Jones Stocks to Research Further and 1 Facing Headwinds

March 09, 2026

Via StockStory

1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid ↗

March 08, 2026

Via The Motley Fool

3 Undervalued Names Too Cheap to Ignore ↗

March 07, 2026

Via MarketBeat

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

Via Finterra

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗

March 05, 2026

Via The Motley Fool

Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era

March 05, 2026

Via Finterra

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

Via MarketMinute

2 High-Flying Stocks With More Upside to Buy and Hold ↗

March 04, 2026

Via The Motley Fool

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗

March 03, 2026

Via Stocktwits

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

Via Stocktwits

USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier

March 02, 2026

Via MarketMinute

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗

March 02, 2026

Via Stocktwits

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc

Via Business Wire

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc.

Via Business Wire

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗

February 28, 2026

Via The Motley Fool

Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety

February 27, 2026

Via MarketMinute

What's going on in today's session: S&P500 movers ↗

February 27, 2026

Via Chartmill

Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag

February 27, 2026

Via MarketMinute

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?

Yes, Merck & Co is publicly traded.

What exchange does Merck & Co trade on?

Merck & Co trades on the New York Stock Exchange

What is the ticker symbol for Merck & Co?

The ticker symbol for Merck & Co is MRK on the New York Stock Exchange

What is the current price of Merck & Co?

The current price of Merck & Co is 115.96

When was Merck & Co last traded?

The last trade of Merck & Co was at 03/13/26 03:40 PM ET

What is the market capitalization of Merck & Co?

The market capitalization of Merck & Co is 293.54B

How many shares of Merck & Co are outstanding?

Merck & Co has 294B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.